hg-u133a cdna microarray chips (Thermo Fisher)
Thermo Fisher is a verified supplier 
Thermo Fisher manufactures this product 
90
Structured Review
Thermo Fisher
hg-u133a cdna microarray chips
Hg U133a Cdna Microarray Chips, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+chip+microarray/pmc04824563-129-14-18
Average 90 stars, based on 1 article reviews
Hg U133a Cdna Microarray Chips, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+chip+microarray/pmc04824563-129-14-18
Average 90 stars, based on 1 article reviews
hg-u133a cdna microarray chips - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Microarray:Article Title: Microfluidic reaction vessel array with patterned films Article Snippet: .. Early biochips were based on the idea of a Article Title: Leveraging Large-Scale Biobanks for Therapeutic Target Discovery. Article Snippet: .. Genotyping of ARIC samples was performed on the Article Title: High-throughput engineered tumor organoids reveal ROCK signaling as an immunotherapeutic target in triple-negative breast cancer. Article Snippet: .. TNBC (IHC) subtypes prognostic analysis Prognostic analysis of TNBC (IHC) subtypes and gene expression studies were performed using bc-GenExMiner v5.2,47 which integrates TCGA, SCAN-B RNA-seq, and Affymetrix®, Article Title: Interleukin-2 receptor γ blocks the development of Leydig cells from stem/progenitor cells in male rats via JAK1-STAT3 pathway and GSDMD-mediated pyroptosis. Article Snippet: Interleukin-2 (IL-2) receptor γ (IL2RG) is present in the Leydig cell lineage, but its functional role remains elusive.. To investigate how IL2RG impacts Leydig cell development from stem cells and elucidate the underlying mechanisms, we used a rat model of ethane dimethanesulfonate (EDS)-induced cell depletion in Wild-type (WT) and Il2rg knockout (KO) mice.. WT and KO male rats received intratesticular IL-2 injections (1 and 10 ng/testis) from day 7 to day 21 post-EDS. Article Title: Leveraging and partitioning polygenic risk scores to identify cancer-related proteins Article Snippet: .. Genotyping of ARIC samples was performed on the Article Title: Empowering chemotherapy-induced antitumor immunity by multi-targeted synergistic combination nanomedicine for triple-negative breast cancer Article Snippet: .. The gene expression profiles are generated through standardized Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Article Title: Enhanced Risk Prediction for Coronary Heart Disease by Leveraging Polygenic Risk Score and Clinical Risk Score in European Hypertensive Adults. Article Snippet: .. SNP genotype data of all participants were acquired from the Affymetrix DNA Array:Article Title: Microfluidic reaction vessel array with patterned films Article Snippet: .. Early biochips were based on the idea of a Immunohistochemistry:Article Title: High-throughput engineered tumor organoids reveal ROCK signaling as an immunotherapeutic target in triple-negative breast cancer. Article Snippet: .. TNBC (IHC) subtypes prognostic analysis Prognostic analysis of TNBC (IHC) subtypes and gene expression studies were performed using bc-GenExMiner v5.2,47 which integrates TCGA, SCAN-B RNA-seq, and Affymetrix®, Gene Expression:Article Title: High-throughput engineered tumor organoids reveal ROCK signaling as an immunotherapeutic target in triple-negative breast cancer. Article Snippet: .. TNBC (IHC) subtypes prognostic analysis Prognostic analysis of TNBC (IHC) subtypes and gene expression studies were performed using bc-GenExMiner v5.2,47 which integrates TCGA, SCAN-B RNA-seq, and Affymetrix®, Article Title: Empowering chemotherapy-induced antitumor immunity by multi-targeted synergistic combination nanomedicine for triple-negative breast cancer Article Snippet: .. The gene expression profiles are generated through standardized RNA Sequencing:Article Title: High-throughput engineered tumor organoids reveal ROCK signaling as an immunotherapeutic target in triple-negative breast cancer. Article Snippet: .. TNBC (IHC) subtypes prognostic analysis Prognostic analysis of TNBC (IHC) subtypes and gene expression studies were performed using bc-GenExMiner v5.2,47 which integrates TCGA, SCAN-B RNA-seq, and Affymetrix®, Expressing:Article Title: Interleukin-2 receptor γ blocks the development of Leydig cells from stem/progenitor cells in male rats via JAK1-STAT3 pathway and GSDMD-mediated pyroptosis. Article Snippet: Interleukin-2 (IL-2) receptor γ (IL2RG) is present in the Leydig cell lineage, but its functional role remains elusive.. To investigate how IL2RG impacts Leydig cell development from stem cells and elucidate the underlying mechanisms, we used a rat model of ethane dimethanesulfonate (EDS)-induced cell depletion in Wild-type (WT) and Il2rg knockout (KO) mice.. WT and KO male rats received intratesticular IL-2 injections (1 and 10 ng/testis) from day 7 to day 21 post-EDS. Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Generated:Article Title: Empowering chemotherapy-induced antitumor immunity by multi-targeted synergistic combination nanomedicine for triple-negative breast cancer Article Snippet: .. The gene expression profiles are generated through standardized RNA Extraction:Article Title: Empowering chemotherapy-induced antitumor immunity by multi-targeted synergistic combination nanomedicine for triple-negative breast cancer Article Snippet: .. The gene expression profiles are generated through standardized Reverse Transcription:Article Title: Empowering chemotherapy-induced antitumor immunity by multi-targeted synergistic combination nanomedicine for triple-negative breast cancer Article Snippet: .. The gene expression profiles are generated through standardized Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Hybridization:Article Title: Empowering chemotherapy-induced antitumor immunity by multi-targeted synergistic combination nanomedicine for triple-negative breast cancer Article Snippet: .. The gene expression profiles are generated through standardized Fluorescence:Article Title: Empowering chemotherapy-induced antitumor immunity by multi-targeted synergistic combination nanomedicine for triple-negative breast cancer Article Snippet: .. The gene expression profiles are generated through standardized Extraction:Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Purification:Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Multiple Displacement Amplification:Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Staining:Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Software:Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Variant Assay:Article Title: Enhanced Risk Prediction for Coronary Heart Disease by Leveraging Polygenic Risk Score and Clinical Risk Score in European Hypertensive Adults. Article Snippet: .. SNP genotype data of all participants were acquired from the Affymetrix |
